文献速递乳腺癌

曲妥珠单抗德鲁替康(DS-8201a)用于既往接受曲妥珠单抗美坦新治疗的晚期HER2阳性乳腺癌患者:一项剂量扩展1期研究

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
PubMed 文献 · Lancet Oncol · 2019-04-29

这项在美国8家、日本6家医院开展的开放标签1期剂量扩展研究,纳入115例既往接受曲妥珠单抗美坦新治疗的HER2阳性晚期乳腺癌患者,给予曲妥珠单抗德鲁替康5.4 mg/kg或6.4 mg/kg每3周静脉给药。111例可评估患者中66例(59.5%,95%CI 49.7-68.7)获确认客观缓解,安全性总体可控,间质性肺病/肺炎20例,其中2例治疗相关死亡。

要点

  • 既往曲妥珠单抗美坦新治疗的HER2阳性晚期乳腺癌中,确认客观缓解率为59.5%(95%CI 49.7-68.7)。
  • 所有115例患者均发生至少1例治疗中出现的不良事件,贫血3级及以上19例(17%)。
  • 研究者报告间质性肺病、肺炎或机化性肺炎20例,含1例3级事件和2例肺炎治疗相关死亡。

核心结论

  • 曲妥珠单抗德鲁替康安全性可控,在既往接受曲妥珠单抗美坦新治疗的HER2阳性乳腺癌患者中显示初步活性。
  • 作者认为这些结果提示有必要在HER2阳性乳腺癌中开展2期和3期临床试验进一步开发。

研究设计与样本

  • 开放标签、剂量递增和剂量扩展1期试验,在美国8家医院和诊所及日本6家医院和诊所开展。
  • 纳入美国至少18岁、日本至少20岁的晚期实体瘤患者,剂量扩展阶段要求HER2表达或突变。
  • 本文分析所有既往接受曲妥珠单抗美坦新治疗、接受推荐扩展剂量5.4 mg/kg或6.4 mg/kg曲妥珠单抗德鲁替康的HER2阳性晚期乳腺癌患者,每3周静脉给药一次。
  • 主要终点为安全性和初步活性(研究者评估的客观缓解比例);活性可评估集为至少接受一剂推荐扩展剂量且基线和治疗后活性数据均有的患者,安全性分析集为至少接受一剂推荐扩展剂量的患者。
  • 2015年8月28日至2018年8月10日,118例HER2阳性乳腺癌患者中115例接受至少一剂推荐扩展剂量曲妥珠单抗德鲁替康治疗。

主要发现

  • 所有115例患者均发生至少1例治疗中出现的不良事件。
  • 常见3级及以上治疗中出现的不良事件包括贫血19例(17/115)、中性粒细胞计数降低16例(14%)、白细胞计数降低10例(9%)、血小板计数降低9例(8%)。
  • 22例(19%)患者发生至少1例严重治疗中出现的不良事件。
  • 研究者报告间质性肺病、肺炎或机化性肺炎20例,包括1例3级事件和2例肺炎治疗相关死亡;另1例与研究治疗无关的死亡原因为疾病进展。
  • 111例可评估患者中66例(59.5%,95%CI 49.7-68.7)获确认客观缓解。

关键数值与推荐

  • 推荐扩展剂量为曲妥珠单抗德鲁替康5.4 mg/kg或6.4 mg/kg,每3周静脉给药一次,直至撤回知情同意、出现不可接受的毒性或疾病进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出这些结果提示有必要在HER2阳性乳腺癌中开展2期和3期临床试验进一步开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent topoisomerase I inhibitor payload. A phase 1, non-randomised, open-label, multiple-dose study was done to assess the safety, tolerability, and activity of trastuzumab deruxtecan in HER2-expressing, advanced solid tumours. The dose escalation (part 1) has previously been reported and the recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg were established. In this Article, we report the safety and preliminary activity results from this phase 1 trial in all patients with HER2-positive advanced-stage breast cancer with previous trastuzumab emtansine treatment who received trastuzumab deruxtecan at the recommended doses for expansion. METHODS: We did an open-label, dose-escalation and dose-expansion phase 1 trial at eight hospitals and clinics in the USA and six in Japan. Eligible patients were at least 18 years old in the USA and at least 20 years of age in Japan and had advanced solid tumours (regardless of HER2 expression in dose escalation or HER2 expression or mutation in dose expansion). The recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg trastuzumab deruxtecan were administered intravenously to patients once every 3 weeks until withdrawal of consent, unacceptable toxicity, or progressive disease. In this Article, all patients with HER2-positive advanced-stage breast cancer with previous trastuzumab emtansine treatment who received trastuzumab deruxtecan at the recommended doses for expansion were analysed together. The primary endpoints of the study were safety and preliminary activity (proportion of patients who achieved an objective response as assessed by the investigators). The activity evaluable set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion, and for whom both baseline and post-treatment activity data were available. The safety analysis set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion. Enrolment for patients with HER2-positive breast cancer has been completed. This trial is registered at ClinicalTrials.gov, number NCT02564900, and ClinicalTrials.jp, number JapicCTI-152978. FINDINGS: Between Aug 28, 2015, and Aug 10, 2018, 115 of 118 patients with HER2-positive breast cancer were treated with at least one dose of trastuzumab deruxtecan at the recommended doses for expansion. All patients had at least one treatment-emergent adverse event. Frequent grade 3 or worse treatment-emergent adverse events included anaemia (19 [17%] of 115) and decreased neutrophil (16 [14%]), white blood cell (ten [9%]), and platelet (nine [8%]) counts. At least one serious treatment-emergent adverse event occurred for 22 (19%) patients. Investigators reported 20 cases of interstitial lung disease, pneumonitis, or organising pneumonia, including one grade 3 event and two treatment-related deaths due to pneumonitis. One death unrelated to study treatment was due to progressive disease. 66 (59·5%; 95% CI 49·7-68·7) of 111 patients had a confirmed objective response. INTERPRETATION: Trastuzumab deruxtecan had a manageable safety profile and showed preliminary activity in trastuzumab emtansine-pretreated patients with HER2-positive breast cancer. These results suggest that further development in phase 2 and 3 clinical trials for HER2-positive breast cancer is warranted. FUNDING: Daiichi Sankyo Co, Ltd.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019. PMID: 31047803. doi:10.1016/S1470-2045(19)30097-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。